回国后：
1. Yan R^#, Liu D^#, Guo H, Liu M, Lv D, Björkblom B, Wu M, Yu H, Leng H, Lu B, Li Y, Gao M, Blom T*, Zhou K*. LAPTM4B counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of SLC7A11 in non-small cell lung cancer. Cell Death Dis. 2024;15(6):436.
2. Yan R^#, Liu D^#, Wang J, Liu M, Guo H, Bai J, Yang S, Chang J, Yao Z, Yang Z, Blom T*, Zhou K*. miR-137–LAPTM4B regulates cytoskeleton organization and cancer metastasis via the RhoA-LIMK-Cofilin pathway in osteosarcoma. Oncogenesis. 2023; 12:25.
3. Liu M, Yan R, Wang J, Yao Z, Fan X, Zhou K*. LAPTM4B-35 promotes cancer cell migration via stimulating integrin beta1 recycling and focal adhesion dynamics. Cancer Sci. 2022;113(6):2022-2033.
4. Zheng W, Ye S, Liu B, Liu D, Yan R, Guo H, Yu H, Hu X, Zhao H, Zhou K*, Li G*. The crosstalk between GBP2 and M2 macrophage promotes the ccRCC progression，Cancer Sci. 2024; 2. Doi: 10.1111/cas.16287.
5.Yang S, Zhou P, Zhang L, Xie X, Zhang Y, Bo K, Xue J, Zhang W, Liao F, Xu P, Hu Y, Yan R, Liu D, Chang J*, Zhou K*. VAMP8 suppresses the metastasis via DDX5/β-catenin signal pathway in osteosarcoma. Cancer Biol Ther. 2023. Doi: 10.1080/15384047.2023.2230641.
6. Zhou K* , Wang W and Tang J*. Editorial: Functional screening for cancer drug discovery: from experimental approaches to data integration. Front Genet. 2023. Doi: 10.3389/fgene.2023.1201454.
7. Yan R, Wang J, Liu M, Zhou K*. CRISPR accelerates the cancer drug discovery. Biocell. 2022; 46(10):1-7.
8. Zhang X, Zhang Y, Liu L, Gong Z*, Zhou K*. Pan-Cancer Analysis Reveals PRIM2 as a Potential Biomarker for Diagnosis, Prognosis, and Immunomodulatory. International Journal of Genomics. 2024;8834415. Doi: 10.1155/2024/8834415. 

回国前：
1. Zhou K^#, Andrea D^#, Hector M, Thomas N, Li S, Young A, IIpo V, Elina I, Tomas Blom*. “A ceramide-regulated element in the late endosomal protein LAPTM4B controls amino acid transporter interaction”. ACS Cent. Sci., 2018; 4 (5): 548–558.
2. Liu M^#, Zhou K^# and Cao Y*. “MCRS1 overexpression, which is specifically inhibited by miR-129-1-3P, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer”. Mol. Cancer. 2014; 13:245. 
3. Zhou K, Andrea D, Elina I, Tomas B*. “Lysosome Associated Protein Transmembrane 4B-24 is the predominant protein isoform in human tissues and undergoes rapid, nutrient regulated turnover”. Am. J. Pathol.,2020; 190(10): 2018-2028. 
4. Liu M^#, Zhou K^#, Huang Y and Cao Y*. “The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway”. J. Exp. Clin. Cancer Res., 2015; 34(1):121. 
5. Andrea D, Zhou K, Nils B, Thomas N, Anders B, Peter M, Elina I, Tomas B. “LAPTM4B controls the sphingolipid and ether lipid signature of small extracellular vesicles”. Biochim. Biophys. Acta. Mol. Cell Biol. Lipids, 2021; 1866(2): 158855.
6. Zhou K^#, Liu M^# and Cao Y*, “New insight into microRNAs function in cancer: oncogene-microRNA-tumor suppressor gene network”. Front. Mol. Biosci., 2017; 4:46. 
7. Liu M^#, Zhou K^# and Yi Cao*, “MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer.” Int. J. Mol. Sci. 2016; 17:1493.
8. Zhou K and Tomas B*. “Trafficking and functions of bioactive sphingolipids: lessons from cells and model membranes.” Lipid Insights. 2015; 8(Suppl 1):11-20.